Meta-Analysis to Evaluate DMARDs for Rheumatoid Arthritis Treatment

Updated June‌ 2, 2025
‍ ⁢

Researchers are‍ conducting a network meta-analysis to assess⁣ the effectiveness and risks of various⁤ disease-modifying ⁢anti-rheumatic drugs (DMARDs) in ‌treating adults with rheumatoid arthritis. The primary goal ⁤is to compare DMARDs used ⁢as a first-line treatment and after conventional synthetic DMARDs or biologic or targeted synthetic DMARDs have⁣ proven ineffective.

The study also ⁣aims to‍ rank ⁣these interventions based on​ their benefits​ and harms. The analysis will be divided into three separate Cochrane Reviews, each⁣ focusing ⁢on ‍a specific patient⁣ population.

One review will examine dmards‌ as an initial therapy ‍for rheumatoid arthritis. A second⁢ will focus on dmards used after conventional ​synthetic ⁢DMARDs have failed. The third‌ review will ⁤analyze DMARDs ‌used after⁤ biologic or targeted‌ synthetic therapies have been unsuccessful. This comprehensive approach seeks to provide a detailed comparison of ​ DMARDs for rheumatoid arthritis treatment, ​informing clinical decisions and improving patient outcomes.

What’s next

The results of ⁢these ⁣meta-analyses will be ⁤published as three separate ⁣Cochrane Reviews, providing clinicians with evidence-based recommendations for selecting the most appropriate DMARD⁤ therapy for their‌ patients.